A Ph2b to Evaluate Tildacerfont in the Reduction of Glucocorticoid Steroid Doses in Adult CAH
Public ClinicalTrials.gov record NCT04544410. Field values are reproduced from the official study page; the official ClinicalTrials.gov record remains the source of truth for eligibility, enrollment, and contact information.
Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.
Official title
A Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Efficacy and Safety of SPR001 (Tildacerfont) in Reducing Supraphysiologic Glucocorticoid Use in Adult Subjects With Classic Congenital Adrenal Hyperplasia
Study identification
- NCT ID
- NCT04544410
- Recruitment status
- Terminated
- Study type
- Interventional
- Phase
- Phase 2
- Lead sponsor
- Spruce Biosciences
- Industry
- Enrollment
- 100 participants
Conditions and interventions
Conditions
Interventions
- Tildacerfont/Placebo Drug
Drug
Eligibility (public fields only)
- Age range
- 18 Years and older
- Sex
- All
- Healthy volunteers
- Healthy volunteers not accepted
This page does not interpret eligibility. Detailed inclusion and exclusion criteria are on the official ClinicalTrials.gov record.
Study timeline
- Start date
- Feb 21, 2021
- Primary completion
- Oct 30, 2024
- Completion
- Jan 30, 2025
- Last update posted
- Sep 30, 2025
2021 – 2025
United States locations
- U.S. sites
- 18
- U.S. states
- 12
- U.S. cities
- 16
| Facility | City | State | ZIP | Site status |
|---|---|---|---|---|
| Spruce Study Site | Birmingham | Alabama | 35294 | — |
| Spruce Study Site | Los Angeles | California | 90027 | — |
| Spruce Study Site | San Diego | California | 92123 | — |
| Spruce Study Site | Indianapolis | Indiana | 46202 | — |
| Spruce Study Site | Baltimore | Maryland | 21287 | — |
| Spruce Biosciences Clinical Site | Ann Arbor | Michigan | 48109 | — |
| Spruce Study Site | Minneapolis | Minnesota | 55454 | — |
| Spruce Study Site | New Brunswick | New Jersey | 08901 | — |
| Spruce Study Site | Canton | Ohio | 44718 | — |
| Spruce Study Site | Cincinnati | Ohio | 45219 | — |
| Spruce Study Site | Cleveland | Ohio | 44195 | — |
| Spruce Study Site | Columbus | Ohio | 43210 | — |
| Spruce Study Site | Philadelphia | Pennsylvania | 19104 | — |
| Spruce Study Site | Philadelphia | Pennsylvania | 19107 | — |
| Spruce Study Site | Philadelphia | Pennsylvania | 19140 | — |
| Spruce Study Site | Providence | Rhode Island | 02903 | — |
| Spruce Study Site | Columbia | South Carolina | 29203 | — |
| Spruce Study Site | Fort Worth | Texas | 76104 | — |
Site contact phone numbers, emails, and investigator names are intentionally not displayed here. Open the official ClinicalTrials.gov record for site contact information.
Non-U.S. locations
This page focuses on the U.S. directory. The official record also lists 25 non-U.S. sites.
About this trial record page
- What this page shows
- Public field values for ClinicalTrials.gov record NCT04544410, including study identification, conditions, interventions, eligibility (age, sex, healthy volunteer), timeline, and U.S. site list.
- What this page does not do
- No medical advice, eligibility judgments, treatment recommendations, study quality scoring, or AI-generated medical summaries. No site contact phone numbers, emails, or investigator names.
- Where the data comes from
- Sourced from the official ClinicalTrials.gov public API. The official record is the source of truth.
- Last refresh
- Last update posted Sep 30, 2025 · Synced May 17, 2026
Related: full search, browse by condition, browse by drug or therapy, browse by sponsor, browse by U.S. city.
Open the official record
The complete protocol, eligibility criteria, and contact information for NCT04544410 live on ClinicalTrials.gov.